Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 7, 2011, Pages 588-592

  Novak, Michael ^a   Schlagenhauf, Axel ^a   Bernhard, Heike ^a   Schweintzger, Sabrina ^a   Leschnik, Bettina ^a   Muntean, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

activated partial thromboplastin time; heparin; neonatal hemostasis; rivaroxaban; thrombin generation

Indexed keywords

HEPARIN; RIVAROXABAN;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GROUPS BY AGE; HEMOSTASIS; HUMAN; NEWBORN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE POOR PLASMA; THROMBOPLASTIN TIME;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XA; FETAL BLOOD; HEPARIN; HUMANS; INFANT, NEWBORN; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; THIOPHENES; THROMBIN; THROMBIN TIME;

EID: 80053612506     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328349f190     Document Type: Article

References (22)

1. David M, Andrew M. Venous thromboembolic complications in children. J Pediatr 1993; 123:337-346. (Pubitemid 23258153)
2. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165-172. (Pubitemid 17111257)
3. Muntean W, Leschnik B, Baier K, Cvirn G, Gallistl S. In vivo thrombin generation in neonates. J Thromb Haemost 2004; 2:2071-2072.
4. Chan AK, Berry LR, Monagle PT, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost 2002; 87:606-613. (Pubitemid 34302948)
5. Cvirn G, Gallistl S, Leschnik B, Muntean W. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb Haemost 2003; 1:263-268.
6. Cvirn G, Gallistl S, Rehak T, Juergens G, Muntean W. Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma. J Thromb Haemost 2003; 1:1785-1790.
7. Fritsch P, Cvirn G, Cimenti C, Baier K, Koestenberger M, Gallistl S, et al. Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor. J Thromb Haemost 2006; 4:1071-1077.
8. Tripodi A, Ramenghi LA, Chantarangkul V, De Carli A, Clerici M, Groppo M, et al. Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests. Haematologica 2008; 93:1256-1259.
9. Baier K, Cvirn G, Fritsch P, Kostenberger M, Gallistl S, Leschnik B, Muntean W. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma. Pediatr Res 2005; 57:685-689. (Pubitemid 40578039)
10. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 2010; 103:1085-1090.
11. Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P. Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children. Br J Haematol 2010; 149:734-738.
12. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P. Research paper: clinical use of unfractionated heparin therapy in children-time for change? Br J Haematol 2010; 150:674-678.
13. Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemost 2010; 8:1290-1294.
14. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor xa inhibitor. J Thromb Haemost 2005; 3:514-521. (Pubitemid 41632877)
15. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5:886-888. (Pubitemid 46563600)
16. Koestenberger M, Gallistl S, Cvirn G, Baier K, Leschnik B, Muntean W. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: An in vitro examination. Thromb Res 2005; 115:135-142. (Pubitemid 39572767)
17. Hemker HC, Giesen P, Dieri RA, Regnault V, Smedt Ed, Wagenvoord R, Béguin TLaS. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4-15. (Pubitemid 37449290)
18. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32:249-253. (Pubitemid 37490547)
19. Newall F, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P, Ignjatovic V. Novel interactions between UFH and TFPI in children. Br J Haematol 2010; 151:376-380.
20. Ignjatovic V, Greenway A, Summerhayes R, Monagle P. Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis. Br J Haematol 2007; 138:366-368. (Pubitemid 47035395)
21. Hemker HC, de Smedt E, Al Dieri R. The contribution of alpha(2)-macroglobulin thrombin to the endogenous thrombin potential. Br J Haematol 2007; 139:513. (Pubitemid 47512193)
22. IgnjatovicV,Summerhayes R, NewallF, Monagle P. Theinvitro response to low-molecular-weight heparin is not age-dependent in children. Thromb Haemost 2010; 103:855-856.